Evidence map›Paper›PMID 35462899›Full record

ReviewFrontiers in pharmacology2022

Pharmacological Properties of Ginsenoside Re.

Xiao-Yan Gao, Guan-Cheng Liu, Jian-Xiu Zhang, Ling-He Wang, Chang Xu, Zi-An Yan, Ao Wang, Yi-Fei Su, Jung-Joon Lee, Guang-Chun Piao and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Research Progress on the Anticancer Effect of Ginsenoside Rh1.Current issues in molecular biology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Ginsenoside Re mitigates AβJournal of ginseng research · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiao-Yan GaoCollege of Pharmacy, Yanbian University, Jilin, China.
Guan-Cheng LiuCollege of Pharmacy, Yanbian University, Jilin, China.
Jian-Xiu ZhangCollege of Pharmacy, Yanbian University, Jilin, China.
Ling-He WangCollege of Integration Science, Yanbian University, Jilin, China.
Chang XuCollege of Pharmacy, Yanbian University, Jilin, China.
Zi-An YanCollege of Integration Science, Yanbian University, Jilin, China.
Ao WangCollege of Pharmacy, Yanbian University, Jilin, China.
Yi-Fei SuCollege of Pharmacy, Yanbian University, Jilin, China.
Jung-Joon LeeKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Jilin, China.
Guang-Chun PiaoCollege of Pharmacy, Yanbian University, Jilin, China.
Hai-Dan YuanCollege of Pharmacy, Yanbian University, Jilin, China.
Yanbian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ginsenoside Re is a protopanaxatriol-type saponin extracted from the berry, leaf, stem, flower bud, and root of

Indexed as

bioactive componentginsenoside Repharmacokineticspharmacological activitiestoxicology

Identifiers

PMID35462899
PMCPMC9019721
OpenAlexW4225539174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.